ClinicalTrials.gg
CompletedNCT01499290Updated Sep 6, 2017Results posted

Compare Ceftazidime-Avibactam + Metronidazole Versus Meropenem for Hospitalized Adults With Complicated Intra-Abdominal Infections

A Phase 3 interventional study of CAZ-AVI and Metronidazole in Complicated Intra-Abdominal Infection, sponsored by Pfizer. Completed at 57 sites in 20 countries. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2017-09-06.

Sponsored by Pfizer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
493
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 19 studies in Intraabdominal Infections by Pfizer — none open to participants now, none under way, none of them phase 3. Intraabdominal Infections · Pfizer.

Enrollment
Largest of 14
493 · median 144
Started
2012
with 1 other
Phase 3
5 of 19
none open now
Registered
10th of 19
by date

Among the 19 studies in Intraabdominal Infections by Pfizer, this one has the largest enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2012, is one of 5 in phase 3, and was the 10th registered.

Intraabdominal Infections

129 studies on the registry are indexed under Intraabdominal Infections; 15 are open to participants now.

Browse Intraabdominal Infections studies →

Open to participants now

None of the 19 studies in Intraabdominal Infections by Pfizer is open now. The open studies under Intraabdominal Infections, anywhere →

Who these studies take

Of the 10 Intraabdominal Infections studies recruiting now, 6 (60%) set no upper age limit and 3 (30%) stop at 75 or younger; 2 take children under 18; 2 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies in Intraabdominal Infections by Pfizer as a file.
02

Study summary

The purpose of this study is to evaluate the effects of Ceftazidime Avibactam plus Metronidazole compared to Meropenem for treating hospitalized patients with complicated intra-abdominal infections.

Read the detailed description

A Phase III, Randomized, Multicenter, Double Blind, Double-Dummy, Parallel-Group, Comparative Study to Determine the Efficacy, Safety, and Tolerability of Ceftazidime Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infections In Hospitalized Adults

03

Conditions studied

  • Complicated Intra-Abdominal Infection

Keywords

  • Ceftazidime
  • Meropenem
  • Metronidazole
  • Anti-Bacterial Agents
  • Anti-Infective Agents
  • Antiprotozoal Agents
  • Antiparasitic Agents
  • cIAI, Complicated Intra-Abdominal Infection
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 to 90 years of age inclusive
  • Female patient is authorized to participate if at least one of the following criteria are met:

    1. Surgical sterilization
    2. Age ≥50 years and as defined by amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments
    3. Age \<50 years and postmenopausal as defined by documented LH and FSH levels in the postmenopausal range PLUS amenorrhea for 12 months or more following cessation of all exogenous hormonal treatments
    4. Patient has a negative serum pregnancy test (serum ß-human chorionic gonadotropin [ß-hCG]) within 1 day prior to study entry, and agrees to use highly effective methods during treatment and for at least 7 days after last dose of IV study therapy
  • Intraoperative/postoperative enrollment with confirmation (presence of pus within the abdominal cavity) of an intra-abdominal infection associated with peritonitis
  • Confirmation of infection by surgical intervention within 24 hours of entry: evidence of systemic inflammatory response; physical findings consistent with intra-abdominal infection; supportive radiologic imaging findings of intra-abdominal infections

Exclusion criteria

Exclusion Criteria:

  • Patient is diagnosed with traumatic bowel perforation undergoing surgery within 12 hours; perforation of gastroduodenal ulcers undergoing surgery within 24 hours. Other intra-abdominal processes in which primary etiology is not likely to be infectious
  • Patient has abdominal wall abscess or bowel obstruction without perforation or ischemic bowel without perforation
  • Patient has suspected intra-abdominal infections due to fungus, parasites, virus or tuberculosis
  • Patient is considered unlikely to survive the 6 to 8 week study period or has a rapidly progressive or terminal illness, including septic shock that is associated with a high risk of mortality
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
493 participants (actual)

Study arms

  • Experimental
    CAZ-AVI + Metronidazole

    IV treatment

    Drug: CAZ-AVI · Drug: Metronidazole

  • Active comparator
    Meropenem

    IV treatment

    Drug: Meropenem

Interventions

  • DrugCAZ-AVI

    Ceftazidime 2000 mg and 500 mg of avibactam

  • 500 mg of Metronidazole

  • 1 gram of Meropenem

06

What researchers measure

Primary outcomes

  1. Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).

    The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA.

    Time frame: TOC: 28 to 35 days after start of study drug

  2. Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).

    The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.

    Time frame: TOC: 28 to 35 days after start of study drug

  3. Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).

    The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: TOC: 28 to 35 days after start of study drug

Secondary outcomes

  1. Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set

    The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: TOC: 28 to 35 days after start of study drug

  2. Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set

    The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: TOC: 28 to 35 days after start of study drug

  3. Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)

    Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.

    Time frame: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug

  4. Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set

    Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

    Time frame: EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug

  5. Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.

    The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: TOC: 28 to 35 days after start of study drug.

  6. Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set

    Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

    Time frame: Test of Cure: 28 to 35 days after start of study drug

  7. Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

    The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

    Time frame: TOC: 28 to 35 days after start of study drug

  8. Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

    Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

    Time frame: Test of Cure: 28 to 35 days after start of study drug

  9. Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry

    Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day.

    Time frame: Test of Cure: 1 to 14 days after start of study drug

  10. Plasma Concentrations for Ceftazidime and Avibactam

    Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations

    Time frame: Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug

07

Results

Posted Mar 1, 2016
Limitations and caveats
This summary describes data collected from two identical CSPs (D4280C00001 and D4280C00005). With agreement from the EMA and the FDA the data have been combined into a single study database.

Participant flow

Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA. First patient enrolled 22 March 2012 and last patient's last visit was 07 April 2014. Patients were adults hospitalised with complicated intra-abdominal infection (cIAI) that required surgery and IV antibiotics.

Participant flow — Overall Study
MilestoneCAZ-AVI + MetronidazoleMeropenem
Started529529
Completed474494
Not completed5535
Withdrew: Withdrawal by subject2215
Withdrew: Not specified in study report115
Withdrew: Condition improved/subject recovered10
Withdrew: Lack of efficacy78
Withdrew: Adverse event147

Outcome measures

PrimaryClinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention is necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, death where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure. Results from two identical protocols D4280C00001 and D4280C00005 combined into a single database with agreement from FDA and EMA.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Response at the Test of Cure (TOC) Visit in the Microbiologically Modified Intent-To-Treat (mMITT) Analysis Set (Primary Outcome for FDA).
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Clinical cure337349
Clinical failure3730
Indeterminate3931
Statistical analysis
  • CAZ-AVI + Metronidazole vs Meropenem · Risk difference (rd): -3.5 · 95% CI -8.64 to 1.58
PrimaryClinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Response at the TOC Visit in the Modified Intent-To-Treat Analysis Set (Co-primary Outcome for Rest of World [ROW]).
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Clinical cure429444
Clinical failure4739
Indeterminate4440
Statistical analysis
  • CAZ-AVI + Metronidazole vs Meropenem · Risk difference (rd): -2.4 · 95% CI -6.90 to 2.10
PrimaryClinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Response at the TOC Visit in the Clinically Evaulable (CE) Analysis Set (Co-primary Outcome for Rest of World [ROW]).
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Clinical cure376385
Clinical failure3431
Statistical analysis
  • CAZ-AVI + Metronidazole vs Meropenem · Risk difference (rd): -0.8 · 95% CI -4.61 to 2.89
SecondaryClinical Cure at TOC in the Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Cure at TOC in the Microbiologically Evaluable Analysis Set
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Clinical cure244272
Clinical failure2115
SecondaryClinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set

The number of patients meeting the cure criteria: complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Cure at TOC in the Extended Microbiologically Evaluable Analysis Set
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Clinical cure248278
Clinical failure2216
SecondaryClinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)

Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary. Indeterminate response are where study data were not available for evaluation of efficacy for any reason, including patient lost to follow-up or assessment not undertaken such that a determination of clinical response could not be made, dDeath where cIAI was clearly noncontributory or circumstances that precluded classification as a cure or failure.

Time frame:
EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU: 42 to 49 days after start of study drug
Reported as:
Number · Participants
Clinical Response by Visit in the Primary Population: Microbiologically Modified Intent-to-Treat (mMITT)
ParticipantsCAZ-AVI + Metronidazole (EOT)Meropenem (EOT)CAZ-AVI + Metronidazole (TOC)Meropenem (TOC)CAZ-AVI + Metronidazole (LFU)Meropenem (LFU)
Clinical cure361379337349340347
Clinical failure301937303831
Indeterminate221239313532
SecondaryPer-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set

Microbiological responses as per the protocoled criteria: responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to a surgical review panel (SRP) assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

Time frame:
EOT: within 24 hours after last dose of study drug. TOC: 28 to 35 days after start of study drug. LFU 42 to 49 days after start of study drug
Reported as:
Number · Participants
Per-patient Microbiological Response in the Microbiologically Modified Intent- To-Treat Analysis Set
ParticipantsCAZ-AVI + Metronidazole (EOT)Meropenem (EOT)CAZ-AVI + Metronidazole (TOC)Meropenem (TOC)CAZ-AVI + Metronidazole (LFU)Meropenem (LFU)
Favourable response362379337349340347
Unfavourable response301937313832
Indeterminate211239303531
SecondaryPer-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.

The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
TOC: 28 to 35 days after start of study drug.
Reported as:
Number · Participants
Per-pathogen Microbiological Response at TOC in the Microbiologically Modified Intent-To-Treat Analysis Set.
ParticipantsCAZ-AVI + MetronidazoleMeropenemCAZ-AVI + Metronidazole (Denominator)Meropenem (Denominator)
Citrobacter freundii complex1491812
Enterobacter aerogenes4555
Enterobacter cloacae11161319
Escherichia coli218249271285
Klebsiella oxytoca14121815
Klebsiella pneumoniae40375149
Proteus mirabilis5789
Pseudomonas aeruginosa30343536
Enterococcus avium810815
Enterococcus faecalis22233128
Enterococcus faecium13181622
Staphylococcus aureus17141814
Streptococcus anginosus group59507261
Streptococcus bovis group2637
Streptococcus mitis group1091511
Bacteroides fragilis45385247
Bacteroides ovatus17172220
Bacteroides stercoris91101
Bacteroides thetaiotaomicron18212225
Bacteroides uniformis4677
Bacteroides vulgatus6689
Clostridium perfringens74104
Eggerthella lenta5758
Parabacteroides distasonis13121613
Parvimonas micra78710
SecondaryClinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set

Complete resolution or significant improvement of signs and symptoms of the index infection such that no further antibacterial therapy, drainage, or surgical intervention was necessary.

Time frame:
Test of Cure: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Clinical Response by Pathogen at TOC for Patients Infected With Ceftazidime-resistant Pathogens in Microbiological Modified Intent to Treat Analysis Set
ParticipantsCAZ-AVI + MetronidazoleMeropenemCAZ-AVI + Metronidazole (Denominator)Meropenem (Denominator)
All39554764
Citrobacter freundii complex1212
Enterobacter aerogenes0101
Enterobacter cloacae2737
Escherichia coli19312437
Klebsiella pneumoniae1091313
Morganella morganii1121
Proteus mirabilis2323
Serratia marcescens1010
Alcaligenes faecalis1212
Comamonas testosteroni1010
Pseudomonas aeruginosa2424
SecondaryFavorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

The number of patients with a favorable per-pathogen microbiological response: favourable microbiological response includes: Eradication Absence of causative pathogen from specimens at the site of infection. Presumed eradication where, repeat cultures were not performed/clinically indicated in a patient who had a clinical response of cure.

Time frame:
TOC: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Favorable Per-pathogen Microbiological Response for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
ParticipantsCAZ-AVI + MetronidazoleMeropenemCAZ-AVI + Metronidazole (Denominator)Meropenem (Denominator)
Citrobacter freundii complex1222
Enterobacter aerogenes0101
Enterobacter cloacae2737
Escherichia coli19312437
Klebsiella pneumoniae1091313
Morganella morganii1121
Proteus mirabilis2323
Serratia marcescens1010
Alcaligenes faecalis1212
Comamonas testosteroni1010
Pseudomonas aeruginosa2424
SecondaryPer-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set

Microbiological responses other than "indeterminate" were classified as "favorable" or "unfavorable." Favorable microbiological response assessments included "eradication" and "presumed eradication." Unfavorable microbiological response assessments included "persistence," "persistence with increasing minimum inhibitory concentration (MIC)," and "presumed persistence." Indeterminate microbiologic response assessments included cases where the clinical response was changed to indeterminate due to an SRP assessment of inadequate source control (ie, circumstances that preclude classification as eradication, presumed eradication, persistence, persistence with increasing MIC, and presumed persistence).

Time frame:
Test of Cure: 28 to 35 days after start of study drug
Reported as:
Number · Participants
Per-patient Microbiological Response at TOC for Patients Infected With Ceftazidime-resistant Pathogens in mMITT Analysis Set
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Favourable3955
Unfavourable71
indeterminate28
SecondaryNumber of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry

Time to first defervescence was calculated for patients with a fever (\>38ºC) at baseline. Defervescence (≤37.8ºC) was defined as the absence of fever based on the highest temperature recorded on each study day.

Time frame:
Test of Cure: 1 to 14 days after start of study drug
Reported as:
Number · Participants
Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry
ParticipantsCAZ-AVI + MetronidazoleMeropenem
Number of Patients Afebrile at Last Observation in the Clinically Evaluable Analysis Set for Patients Who Have Fever at Study Entry8472
SecondaryPlasma Concentrations for Ceftazidime and Avibactam

Blood samples were taken from all patients on Day 3 for the pharmacokinetic evaluation of ceftazidime and avibactam plasma concentrations

Time frame:
Anytime within 15 minutes prior to or after stopping study drug, anytime between 30 and 90 minutes after stopping study drug, anytime between 300 minutes and 360 minutes after stopping study drug
Reported as:
Geometric mean · (NG/ML)
Plasma Concentrations for Ceftazidime and Avibactam
(NG/ML)CAZ (1)AVI (1)CAZ (2)AVI (2)CAZ (3)AVI (3)
Plasma Concentrations for Ceftazidime and Avibactam50823.0 (171 to 3110000)9229.4 (13 to 693000)40053.1 (155 to 235000)7163.9 (15 to 46800)10967.6 (159 to 151000)1690.7 (14 to 30800)

Adverse events

Collected over Adverse event data were collected from the screening/consent visit until the late follow-up visit (ie Day -1/0 to Day 42).. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
CAZ-AVI + Metronidazole—17/529 (3.2%)184/529 (34.8%)
Meropenem—15/529 (2.8%)152/529 (28.7%)
Most frequent serious events
Showing 10 of 75
Most frequent serious events
EventCAZ-AVI + MetronidazoleMeropenem
Renal failure acuteRenal and urinary disorders5/5290/529
Respiratory failureRespiratory, thoracic and mediastinal disorders3/5293/529
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/5291/529
Myocardial infarctionCardiac disorders1/5292/529
Transaminases increasedInvestigations0/5292/529
Gastrointestinal stoma necrosisInjury, poisoning and procedural complications2/5290/529
Abdominal abscessInfections and infestations0/5292/529
BronchopneumoniaInfections and infestations2/5292/529
Candida sepsisInfections and infestations2/5290/529
Cardiac failureCardiac disorders2/5291/529
Most frequent other events
Showing 10 of 14
Most frequent other events
EventCAZ-AVI + MetronidazoleMeropenem
DiarrhoeaGastrointestinal disorders40/52917/529
NauseaGastrointestinal disorders36/52924/529
HypertensionVascular disorders15/52924/529
VomitingGastrointestinal disorders24/52910/529
PyrexiaGeneral disorders24/52924/529
ConstipationGastrointestinal disorders8/52920/529
HeadacheNervous system disorders15/5299/529
Wound infectionInfections and infestations13/52911/529
CoughRespiratory, thoracic and mediastinal disorders11/52913/529
HypotensionVascular disorders12/52912/529

Baseline characteristics

The MITT analysis set includes all patients who met the disease definition for cIAI and received at least 1 dose of study drug. 15 patients excluded received at least one dose of study drug but failed the minimum disease criteria.

Age, Continuous
Age, Continuous(Years)CAZ-AVI + MetronidazoleMeropenemTotal
Mean49.8 ± 17.4850.3 ± 18.2950.0 ± 17.88
Sex: Female, Male
Sex: Female, Male(Participants)CAZ-AVI + MetronidazoleMeropenemTotal
Female194191385
Male326332658
08

Study locations

57 sites
  • Research Site
    Chula Vista, California, United States
  • Research Site
    San Diego, California, United States
  • Research Site
    Saint Louis, Missouri, United States
  • Research Site
    Somers Point, New Jersey, United States
  • Research Site
    Córdoba, Argentina
  • Research Site
    Rosario, Argentina
  • Research Site
    Ruse, Bulgaria
  • Research Site
    Varna, Bulgaria
  • Research Site
    Zagreb, Croatia
  • Research Site
    Decin, Czechia
  • Research Site
    Hradec Kralove, Czechia
  • Research Site
    Jihlava, Czechia
  • Research Site
    Olomouc, Czechia
  • Research Site
    Praha 10, Czechia
  • Research Site
    Praha 5, Czechia
  • Research Site
    Teplice, Czechia
  • Research Site
    Budapest, Hungary
  • Research Site
    Székesfehérvár, Hungary
  • Research Site
    Bangalore, India
  • Research Site
    Pune, India
  • Research Site
    Trivandrum, India
  • Research Site
    Vadodara, India
  • Research Site
    Hadera, Israel
  • Research Site
    Haifa, Israel
  • Research Site
    Riga, Latvia
  • Research Site
    Alor Setar, Malaysia
  • Research Site
    Durango, Mexico
  • Research Site
    Guadalajara, Jalisco, Mexico
  • Research Site
    Mexico City, Mexico
  • Research Site
    Enschede, Netherlands
  • Research Site
    s-Hertogenbosch, Netherlands
  • Research Site
    Arequipa, Peru
  • Research Site
    Cercardo de Lima, Peru
  • Research Site
    Lima, Peru
  • Research Site
    Trujillo, Peru
  • Research Site
    Cluj-Napoca, Romania
  • Research Site
    Iasi, Romania
  • Research Site
    Kemerovo, Russian Federation
  • Research Site
    Moscow, Russian Federation
  • Research Site
    Saratov, Russian Federation
  • Research Site
    Vsevolozhsk, Russian Federation
  • Research Site
    Pretoria, South Africa
  • Research Site
    Alcorcón, Spain
  • Research Site
    Elche, Spain
  • Research Site
    Sabadell(Barcelona), Spain
  • Research Site
    Kaohsiung, Taiwan
  • Research Site
    Taichung, Taiwan
  • Research Site
    Tainan, Taiwan
  • Research Site
    Taipei, Taiwan
  • Research Site
    Bangkok, Thailand
  • Research Site
    Khon Kaen, Thailand
  • Research Site
    Phisanulok, Thailand
  • Research Site
    Dnipropetrovsk, Ukraine
  • Research Site
    Ivano-Frankivsk, Ukraine
  • Research Site
    Kharkov, Ukraine
  • Research Site
    Kyiv, Ukraine
  • Research Site
    Zaporizhzhya, Ukraine
09

References and documents

Publications

  • Mazuski JE, Gasink LB, Armstrong J, Broadhurst H, Stone GG, Rank D, Llorens L, Newell P, Pachl J. Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program. Clin Infect Dis. 2016 Jun 1;62(11):1380-1389. doi: 10.1093/cid/ciw133. Epub 2016 Mar 8. PubMed 26962078 ↗
  • Cheng K, Newell P, Chow JW, Broadhurst H, Wilson D, Yates K, Wardman A. Safety Profile of Ceftazidime-Avibactam: Pooled Data from the Adult Phase II and Phase III Clinical Trial Programme. Drug Saf. 2020 Aug;43(8):751-766. doi: 10.1007/s40264-020-00934-3. PubMed 32602065 ↗
  • Kongnakorn T, Eckmann C, Bassetti M, Tichy E, Di Virgilio R, Baillon-Plot N, Charbonneau C. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrob Resist Infect Control. 2019 Dec 21;8:204. doi: 10.1186/s13756-019-0652-x. eCollection 2019. PubMed 31890160 ↗
  • Li J, Lovern M, Green ML, Chiu J, Zhou D, Comisar C, Xiong Y, Hing J, MacPherson M, Wright JG, Riccobene T, Carrothers TJ, Das S. Ceftazidime-Avibactam Population Pharmacokinetic Modeling and Pharmacodynamic Target Attainment Across Adult Indications and Patient Subgroups. Clin Transl Sci. 2019 Mar;12(2):151-163. doi: 10.1111/cts.12585. Epub 2018 Sep 28. PubMed 30221827 ↗
  • Nichols WW, Stone GG, Newell P, Broadhurst H, Wardman A, MacPherson M, Yates K, Riccobene T, Critchley IA, Das S. Ceftazidime-Avibactam Susceptibility Breakpoints against Enterobacteriaceae and Pseudomonas aeruginosa. Antimicrob Agents Chemother. 2018 Oct 24;62(11):e02590-17. doi: 10.1128/AAC.02590-17. Print 2018 Nov. PubMed 30061279 ↗
  • Stone GG, Newell P, Gasink LB, Broadhurst H, Wardman A, Yates K, Chen Z, Song J, Chow JW. Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme. J Antimicrob Chemother. 2018 Sep 1;73(9):2519-2523. doi: 10.1093/jac/dky204. PubMed 29912399 ↗
  • Stone GG, Newell P, Bradford PA. In Vitro Activity of Ceftazidime-Avibactam against Isolates from Patients in a Phase 3 Clinical Trial for Treatment of Complicated Intra-abdominal Infections. Antimicrob Agents Chemother. 2018 Jun 26;62(7):e02584-17. doi: 10.1128/AAC.02584-17. Print 2018 Jul. PubMed 29686147 ↗
  • Mendes RE, Castanheira M, Woosley LN, Stone GG, Bradford PA, Flamm RK. Molecular beta-Lactamase Characterization of Aerobic Gram-Negative Pathogens Recovered from Patients Enrolled in the Ceftazidime-Avibactam Phase 3 Trials for Complicated Intra-abdominal Infections, with Efficacies Analyzed against Susceptible and Resistant Subsets. Antimicrob Agents Chemother. 2017 May 24;61(6):e02447-16. doi: 10.1128/AAC.02447-16. Print 2017 Jun. PubMed 28348155 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2012, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2016, 1 year 11 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 19, 2011
First posted
Dec 26, 2011
Start
Mar 2012
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Results first posted
Mar 1, 2016
Last update
Sep 6, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 6, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01499290
Lead sponsor
Pfizer
Collaborators
Forest Laboratories
Responsible party
Sponsor
First posted
Dec 26, 2011
Start date
Mar 2012
Primary completion
Apr 2014
Completion
Apr 2014
Results posted
Mar 1, 2016
Last update
Sep 6, 2017

Study contacts

Paul Newell, MBBS, MRCP
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metronidazole

Start the discussion